



09/284,424



RN 177742-23-3 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-2-oxo-3-[[[6-oxo-5-  
 [[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-  
 pyrimidinyl]acetyl]amino]butyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177742-24-4 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-  
 [[[(phenylmethyl)amino]carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-  
 oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/284,424



RN 177742-25-5 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[5-[[2,5-dihydro-2-furanyl)carbonyl]amino]-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 177742-26-6 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[5-[[6-(dimethylamino)-1-oxohexyl]amino]-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 177742-27-7 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-[(phenylsulfonyl)amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177742-28-8 CAPLUS


CN Benzoic acid, 2,4-dichloro-, 3-[[[5-amino-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-4-carboxy-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 22 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1996:317557 CAPLUS  
 DOCUMENT NUMBER: 125:48676  
 TITLE: Interleukin-1.beta. converting enzyme inhibition  
 blocks progression of type II collagen-induced  
 arthritis in mice  
 AUTHOR(S): Ku, George; Faust, Ted; Lauffer, Linda L.;  
 Livingston,  
 David J.; Harding, Matthew W.  
 CORPORATE SOURCE: Vertex Pharmaceuticals Incorporated, Cambridge, MA,  
 01239, USA  
 SOURCE: Cytokine (1996), 8(5), 377-386  
 CODEN: CYTIE9; ISSN: 1043-4666  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 151594-01-3, VE 16084  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (interleukin-1.beta. converting enzyme inhibitors VE-13045 and  
 VE-16084  
 block progression of type II collagen-induced arthritis in mice)  
 RN 151594-01-3 CAPLUS  
 CN L-Alaninamide,  
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 23 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1996:214750 CAPLUS  
 DOCUMENT NUMBER: 124:290273  
 TITLE: Preparation of peptide analogs as inhibitors of  
 interleukin-1 beta converting enzyme (ICE)  
 INVENTOR(S): Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David  
 J.;  
 Mullican, Michael D.; Murcko, Mark A.; Livingston,  
 David J.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorp., USA  
 SOURCE: PCT Int. Appl., 374 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535308	A1	19951228	WO 1995-US7617	19950616
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5756466	A	19980526	US 1994-261452	19940617
US 5656627	A	19970812	US 1995-405581	19950317
US 5847135	A	19981208	US 1995-440898	19950525
AU 9529446	A1	19960115	AU 1995-29446	19950616
EP 784628	A1	19970723	EP 1995-925257	19950616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9508051	A	19971021	BR 1995-8051	19950616
JP 10504285	T2	19980428	JP 1995-502478	19950616
NO 9605365	A	19970217	NO 1996-5365	19961213
FI 9605036	A	19970214	FI 1996-5036	19961216
PRIORITY APPLN. INFO.:				
			US 1994-261452	19940617
			US 1995-405581	19950317
			US 1995-440898	19950525
			WO 1995-US7617	19950616

09/284,424

OTHER SOURCE(S): MARPAT 124:290273

IT 175209-21-9P 175209-22-0P 175209-42-4P  
175209-46-8P 175209-83-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175209-21-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[[ (phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 175209-42-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[ (2S)-2-[(1H-imidazol-2-ylcarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/284,424




RN 175209-46-8 CAPLUS  
CN Benzoic acid, 2,6-dichloro-,  
(3S)-4-carboxy-2-oxo-3-[[ (2S)-1-oxo-2-[2-oxo-  
3-[(1-oxo-3-phenylpropyl)amino]-1(2H)-pyridinyl]propyl]amino]butyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-83-3 CAPLUS  
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[(3S)-2,3,4,5-  
tetrahydro-2-oxo-5-(1-oxo-3-phenylpropyl)-3-[(1-oxo-3-phenylpropyl)amino]-  
1H-1,5-benzodiazepin-1-yl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 24 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:996306 CAPLUS

DOCUMENT NUMBER: 124:146843

TITLE: Preparation of N-(pyrimidinyl)aspartic acid  
 .alpha.-substituted Me ketones and aspartic acid  
 aldehydes as interleukin-1.beta. protease inhibitors

INVENTOR(S): Dolle, Roland E.; Prouty, Catherine P.; Chaturvedula,  
 Prasad V.; Schmidt, Stanley J.

PATENT ASSIGNEE(S): Sanofi Winthrop, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526958	A1	19951012	WO 1995-US3909	19950329
W: AU, CA, CN, FI, HU, JP, MX, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186511	AA	19951012	CA 1995-2186511	19950329
AU 9522323	A1	19951023	AU 1995-22323	19950329
AU 703451	B2	19990325		
EP 752987	A1	19970115	EP 1995-915448	19950329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1149292	A	19970507	CN 1995-193258	19950329
HU 75715	A2	19970528	HU 1996-2664	19950329
JP 09511249	T2	19971111	JP 1995-525821	19950329
NO 9604058	A	19960926	NO 1996-4058	19960926
FI 9603897	A	19960927	FI 1996-3897	19960927
PRIORITY APPLN. INFO.:			US 1994-221712	19940331
			WO 1995-US3909	19950329

OTHER SOURCE(S): MARPAT 124:146843

IT 173305-25-4P 173305-26-5P 173305-41-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)

(prepn. of N-(pyrimidinyl)aspartic acid .alpha.-substituted Me ketones  
 and aspartic acid aldehydes as interleukin-1.beta. protease  
 inhibitors)


RN 173305-25-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-,  
 (3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-  
 5-[[[phenylmethoxy]carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-  
 oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/284,424



RN 173305-26-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-5-[[4-(methylthio)benzoyl]amino]-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173305-41-4 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 25 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1995:874345 CAPLUS  
 DOCUMENT NUMBER: 124:56682  
 TITLE: Synthesis and evaluation of diacylhydrazines as inhibitors of the interleukin-1.β. converting enzyme (ICE)  
 AUTHOR(S): Graybill, Todd L.; Dolle, Roland E.; Helaszek, Carla T.; Ator, Mark A.; Strasters, Joost  
 CORPORATE SOURCE: Department Medicinal Chemistry, Biochemistry, Analytical Chemistry, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA, 19426, USA  
 SOURCE: Bioorg. Med. Chem. Lett. (1995), 5(11), 1197-202  
 CODEN: BMCLE8; ISSN: 0960-894X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 151594-01-3  
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
 (prepn., hydrolytic stability, and interleukin-1.β. converting enzyme inhibitory activity of peptidyl diacylhydrazine inhibitors)  
 RN 151594-01-3 CAPLUS  
 CN L-Alaninamide,  
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 26 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1995:819770 CAPLUS  
 DOCUMENT NUMBER: 123:225595  
 TITLE: Secretion of human monocyte mature IL-1.beta.:  
 optimization of culture conditions and inhibition by  
 ICE inhibitors  
 AUTHOR(S): Uhl, J.; Krasney, P.; Brophy, L.; Arnold, R.; Dolle,  
 R.; Helaszek, C.; Miller, R.; Gilman, S.; Ator, M.  
 CORPORATE SOURCE: Dep. Inflammation, Collegeville, PA, 19426, USA  
 SOURCE: Inflammation Res. (1995), 44(Suppl. 2), S211-S212  
 CODEN: INREFB; ISSN: 1023-3830  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 151594-01-3 153088-74-5  
 RL: BAC (Biological activity or effector, except adverse); BIOL  
 (Biological study)  
 (interleukin-1.beta. converting enzyme inhibitors suppress the  
 secretion of mature interleukin-1.beta. by human monocytes)  
 RN 151594-01-3 CAPLUS  
 CN L-Alaninamide,  
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-  
 [[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:735232 CAPLUS

DOCUMENT NUMBER: 123:170185

TITLE: Preparation of peptide analogs as irreversible interleukin-1.beta. protease inhibitors.

INVENTOR(S): Dolle, Roland E.; Osifo, Irennegbe K.; Schmidt, Stanley J.; Hoyer, Denton W.; Ross, Tina M.; Chaturvedula, Prasad; Prouty, Catherine P.; Awad, Mohamed M.; Salvino, Joseph M.; et al.

PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 623592	A1	19941109	EP 1994-201161	19940427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2122227	AA	19941030	CA 1994-2122227	19940426
JP 07025865	A2	19950127	JP 1994-89532	19940427
AU 9460752	A1	19941103	AU 1994-60752	19940428
AU 676887	B2	19970327		
IL 109471	A1	19980222	IL 1994-109471	19940428
FI 9402005	A	19941030	FI 1994-2005	19940429
NO 9401580	A	19941031	NO 1994-1580	19940429
HU 68563	A2	19950628	HU 1994-1251	19940429
			US 1993-55051	19930429

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 123:170185

IT 151594-01-3P 153088-74-5P 162852-51-9P

162852-52-0P 162852-53-1P 162852-54-2P

162852-55-3P 166388-79-0P 166388-80-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide ketone analogs as irreversible interleukin-1.beta. protease inhibitors)

RN 151594-01-3 CAPLUS


CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-

[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 153088-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-51-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[3-(1H-imidazol-4-yl)-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[(methoxycarbonyl)amino]acetyl]

09/284,424

amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-53-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-54-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-(2-thienyl)propyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-55-3 CAPLUS

09/284,424

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166388-79-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-phenylpropyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166388-80-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-2-oxo-3-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]butyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 28 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1995:686700 CAPLUS  
 DOCUMENT NUMBER: 123:84008  
 TITLE: Preparation of peptides inhibiting interleukin  
 1.beta.  
 release useful as antiinflammatory agents.  
 INVENTOR(S): Heng, Richard; Leutwiler, Albert; Revesz, Laszlo;  
 Wuethrich, Hans-Juerg  
 PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-GmbH;  
 Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SOURCE: Eur. Pat. Appl., 23 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 618223	A2	19941005	EP 1994-810137	19940303
EP 618223	A3	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2117121	AA	19940909	CA 1994-2117121	19940307
JP 06340691	A2	19941213	JP 1994-35748	19940307
PRIORITY APPLN. INFO.:			GB 1993-4686	19930308
			GB 1993-5382	19930316
			GB 1993-5386	19930316
			GB 1993-8328	19930422
			GB 1993-8329	19930422
			GB 1993-8330	19930422

OTHER SOURCE(S): MARPAT 123:84008  
 IT 165112-13-0P 165112-16-3P 165112-18-5P  
 165112-26-5P 165112-28-7P 165112-30-1P  
 165112-33-4P 165112-35-6P 165112-62-9P  
 165112-85-6P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (prepn. of peptides inhibiting interleukin 1.beta. release useful as  
 antiinflammatory agents)  
 RN 165112-13-0 CAPLUS  
 CN L-Alaninamide,  
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-  
 oxo-3-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)oxy]propyl]-, (R)- (9CI)  
 (CA  
 INDEX NAME)

Absolute stereochemistry.




09/284,424



RN 165112-16-3 CAPLUS

CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[3-[(9-acridinylcarbonyl)oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165112-18-5 CAPLUS

CN L-Alaninamide,  
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[(1H-indol-3-ylcarbonyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165112-26-5 CAPLUS

CN L-Alaninamide,  
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[[2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]oxy]-2-oxopropyl]- (9CI)

09/284,424

(CA INDEX NAME)

Absolute stereochemistry.




RN 165112-28-7 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[[ (2-methoxy-3-methyl-4-quinolinyl)carbonyl]oxy]-2-oxopropyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 165112-30-1 CAPLUS


CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[[ (1,3-dimethyl-1H-indol-2-yl)carbonyl]oxy]-2-oxopropyl]- (9CI) (CA  
INDEX  
NAME)

Absolute stereochemistry.



09/284,424




RN 165112-33-4 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-[(9H-xanthen-9-ylcarbonyl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165112-35-6 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(diphenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165112-62-9 CAPLUS

CN 2,4-Dioxo-7,10-diazatridecan-13-oic acid, 11-[[[(2,6-dichlorobenzoyl)oxy]acetyl]-8-methyl-5-(1-methylethyl)-3,6,9-trioxo-1-phenyl]- (9CI) (CA INDEX NAME)

09/284,424




RN 165112-85-6 CAPLUS

CN Glycinamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N2-(2,3-dihydro-1H-inden-2-yl)-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 29 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:388930 CAPLUS

DOCUMENT NUMBER: 122:281409

TITLE: Structural and stereochemical requirements of  
time-dependent inactivators of the

interleukin-1.beta.

converting enzyme

AUTHOR(S):

Prasad, C. V. C.; Prouty, Catherine P.; Hoyer,

Denton;

Ross, Tina M.; Salvino, Joseph M.; Awad, Mohamad;  
Graybill, Todd L.; Schmidt, Stanley J.; Osifo, I.  
Kelly; et al.


CORPORATE SOURCE:

Department of Medicinal Chemistry, Sterling Winthrop  
Pharmaceuticals Research Division, Collegeville, PA,  
19426, USA

09/284,424


SOURCE: Bioorg. Med. Chem. Lett. (1995), 5(4), 315-18  
CODEN: BMCLE8; ISSN: 0960-894X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 151594-01-3 153088-74-5 162852-51-9  
162852-52-0 162852-53-1 162852-54-2  
162852-55-3 162852-56-4 162852-57-5  
162990-39-8  
RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)  
(structural and stereochem. requirements of time-dependent  
inactivators  
of interleukin-1.beta. converting enzyme)  
RN 151594-01-3 CAPLUS  
CN L-Alaninamide,  
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS  
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[ (2S)-3-methyl-1-oxo-2-  
[[ (phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 162852-51-9 CAPLUS  
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3-(1H-imidazol-4-yl)-2-  
[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester,  
[S-(R\*,R\*)]-

09/284,424

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-,  
4-carboxy-3-[[[(methoxycarbonyl)amino]acetyl]  
amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-53-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162852-54-2 CAPLUS

09/284,424

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-1-oxo-3-(2-thienyl)propyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-55-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162852-56-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-2-oxo-3-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]butyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/284,424

RN 162852-57-5 CAPLUS

CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 162990-39-8 CAPLUS

CN D-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:326801 CAPLUS

DOCUMENT NUMBER: 122:103682

TITLE: Inhibition of mature IL-1.β. production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1.β. converting enzyme  
AUTHOR(S): Miller, Bruce E.; Krasney, Philip A.; Gauvin, Donna M.; Holbrook, Kim B.; Koonz, David J.; Abruzzese, Ronald V.; Miller, Robert E.; Pagani, Karen A.;

Dolle,

Roland E.; et al.

CORPORATE SOURCE:

Research Division, Sterling Winthrop Pharmaceuticals, Collegeville, PA, 19426, USA

SOURCE:

J. Immunol. (1995), 154(3), 1331-8  
CODEN: JOIMA3; ISSN: 0022-1767



09/284,424

DOCUMENT TYPE: Journal  
LANGUAGE: English

IT 151594-01-3

RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)

(inhibition of mature IL-1.β. prodn. in murine macrophages and an  
inflammation model by IL-1.β. converting enzyme inhibitor WIN


67694)

RN 151594-01-3 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-  
[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 31 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:297974 CAPLUS

DOCUMENT NUMBER: 122:45691

TITLE: Aspartyl .α.-((Diphenylphosphinyl)oxy)methyl  
Ketones as Novel Inhibitors of Interleukin-1.β.  
Converting Enzyme. Utility of the Diphenylphosphinic  
Acid Leaving Group for the Inhibition of Cysteine  
Proteases

AUTHOR(S): Dolle, Roland E.; Singh, Jasbir; Whipple, David;  
Osifo, I. Kelly; Speier, Gary; Graybill, Todd L.;  
Gregory, Jill S.; Harris, Alex L.; Helaszek, Carla

T.; et al.

CORPORATE SOURCE: Department of Medicinal Chemistry, Sterling Winthrop  
Pharmaceuticals Research Division, Collegeville, PA,  
19426, USA

SOURCE: J. Med. Chem. (1995), 38(2), 220-2  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal  
LANGUAGE: English

IT 153088-74-5

RL: BAC (Biological activity or effector, except adverse); PRP  
(Properties); BIOL (Biological study)


(aspartyl ((diphenylphosphinyl)oxy)methyl ketones as novel inhibitors  
of interleukin-1.β. converting enzyme in relation to utility of  
diphenylphosphinic acid leaving group for inhibition of cysteine  
proteases)

RN 153088-74-5 CAPLUS

09/284,424

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(2S)-3-methyl-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 32 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:66276 CAPLUS

DOCUMENT NUMBER: 122:122694

TITLE: Activated ketones as potent reversible inhibitors of interleukin-1.β. converting enzyme

AUTHOR(S): Mjalli, Adnan M. M.; Chapman, Kevin T.; MacCoss, Malcolm; Thornberry, Nancy A.; Peterson, Erin P.  
CORPORATE SOURCE: Dep. Med. Chem. Res., Merck Res. Lab., Rahway, NJ, 07065, USA

SOURCE: Bioorg. Med. Chem. Lett. (1994), 4(16), 1965-8  
CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 160837-67-2

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)


(activated ketones as potent reversible inhibitors of interleukin-1.β. converting enzyme)

RN 160837-67-2 CAPLUS

CN L-Alaninamide,


N-(1-oxo-3-phenylpropyl)-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-(1-oxo-3-phenylpropoxy)propyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Chemical structure of compound 10: A 2,6-difluorophenyl group is connected via an ester linkage to a chain containing two thioamide groups. The first thioamide is linked to a chiral center with a methyl group and a hydrogen atom. The second thioamide is linked to a chiral center with an isopropyl group and a hydrogen atom. The chain ends with a carboxylic acid group.

Absolute stereochemistry.




09/284,424

RN 154674-81-4 CAPLUS  
CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-  
[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

RN 154674-82-5 CAPLUS  
CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-3-[[2,6-  
bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

—OH


RN 154674-84-7 CAPLUS  
 CN L-Alaninamide,  
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-  
 3-[(2,6-dihydroxybenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154674-86-9 CAPLUS  
 CN L-Alaninamide,  
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-  
 3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154719-25-2 CAPLUS  
 CN L-Lysinamide, N-acetyl-L-tyrosyl-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-  
 dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-  
 d]imidazol-4-yl)-1-oxopentyl]-, [3aS-[3a.alpha.,4.beta.(R\*),6a.alpha.]]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



09/284,424


DOCUMENT NUMBER: 120:152995  
TITLE: P1 Aspartate-Based Peptide .alpha.-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1.beta.-Converting Enzyme  
AUTHOR(S): Dolle, Roland E.; Hoyer, Denton; Prasad, C. V. C.; Schmidt, Stanley J.; Helaszek, Carla T.; Miller, Robert E.; Ator, Mark A.  
CORPORATE SOURCE: Department of Medicinal Chemistry and Enzymology and Receptor Biochemistry, Collegeville, PA, 19426, USA  
SOURCE: J. Med. Chem. (1994), 37(5), 563-4  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 151594-01-3P 153088-74-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of and interleukin-1.beta.-converting enzyme inhibition by, structure in relation to)  
RN 151594-01-3 CAPLUS  
CN L-Alaninamide,  
N-[ (phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153088-74-5 CAPLUS  
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[ (2S)-3-methyl-1-oxo-2-[[ (phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/284,424


L4 ANSWER 35 OF 36 CAPLUS COPYRIGHT 1999 ACS  
ACCESSION NUMBER: 1994:77637 CAPLUS  
DOCUMENT NUMBER: 120:77637  
TITLE: Preparation of peptides useful for inhibiting  
IL-1.beta. release  
INVENTOR(S): Heng, Richard; Payne, Trevor Glyn; Revesz, Laszlo;  
Weidmann, Beat  
PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.,  
Austria; Sandoz-Patent-G.m.b.H.; Sandoz Ltd.  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9309135	A1	19930513	WO 1992-EP2472	19921029
W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9228852	A1	19930607	AU 1992-28852	19921029
EP 611375	A1	19940824	EP 1992-922580	19921029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
JP 07500828	T2	19950126	JP 1992-508146	19921029
HU 68200	A2	19950529	HU 1994-1303	19921029
ZA 9208511	A	19940504	ZA 1992-8511	19921104
CN 1094730	A	19941109	CN 1993-105500	19930503
NO 9401629	A	19940704	NO 1994-1629	19940503
FI 9402061	A	19940504	FI 1994-2061	19940504
PRIORITY APPLN. INFO.:			GB 1991-23326	19911104
			WO 1992-EP2472	19921029

OTHER SOURCE(S): MARPAT 120:77637  
IT 151544-27-3P 151544-31-9P 151544-35-3P  
151544-36-4P 151544-42-2P 151594-01-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as inhibitor of IL-1.beta. release)  
RN 151544-27-3 CAPLUS  
CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-  
(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI)  
(CA INDEX NAME)




09/284,424



RN 151544-31-9 CAPLUS

CN L-Histidinamide,


N-[(phenylmethoxy)carbonyl]-D-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)



RN 151544-35-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3-(1H-imidazol-4-yl)-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



09/284,424


RN 151544-36-4 CAPLUS  
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3-(1H-imidazol-4-yl)-1-oxo-2-[[3-(phenylmethoxy)benzoyl]amino]propyl]amino]-2-oxobutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151544-42-2 CAPLUS  
CN L-Alaninamide,  
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151594-01-3 CAPLUS  
CN L-Alaninamide,  
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/284,424




L4 ANSWER 36 OF 36 CAPLUS COPYRIGHT 1999 ACS  
 ACCESSION NUMBER: 1993:641381 CAPLUS  
 DOCUMENT NUMBER: 119:241381  
 TITLE: Peptidyl derivatives as inhibitors of interleukin-1.β. converting enzyme  
 INVENTOR(S): Chapman, Kevin T.; Maccoss, Malcolm; Mjalli, Adnan  
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA  
 SOURCE: PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316710	A1	19930902	WO 1993-US1321	19930212
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9336668	A1	19930913	AU 1993-36668	19930212
EP 627926	A1	19941214	EP 1993-905939	19930212
EP 627926	B1	19980805		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07504194	T2	19950511	JP 1993-514912	19930212
AT 169224	E	19980815	AT 1993-905939	19930212
ES 2118940	T3	19981001	ES 1993-905939	19930212
US 5430128	A	19950704	US 1994-342991	19941121
PRIORITY APPLN. INFO.:			US 1992-839590	19920221
			WO 1993-US1321	19930212
			US 1993-67412	19930525

OTHER SOURCE(S): MARPAT 119:241381  
 IT 151272-16-1P 151272-17-2P 151272-18-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of and interleukin-1-mediated diseases treatment with, interleukin-1.β. converting enzyme inhibition in relation to)  
 RN 151272-16-1 CAPLUS  
 CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-[[2,6-bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 151272-17-2 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-(benzoyloxy)-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 151272-18-3 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-[(pentafluorobenzoyl)oxy]propyl]-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



09/284,424

PAGE 1-B

